BioSpace News Archive

The Company also summarized recent program updates and reiterated full-year 2017 financial guidance.

Paratek reported a net loss of $21.3 million, or ($0.77) per share, for the quarter ended September 30, 2017 compared to a net loss of $23.6 million, or ($1.04) per share, for the same period in 2016.

Stargardt disease is the most common form of inherited juvenile macular dystrophy with a prevalence of one in 10,000.

Science Exchange announced today that ReproCELL has selected the Science Exchange platform as the primary marketplace to offer access to its predictive drug discovery assays for the biopharma research community.

In cutting-edge research aimed at breeding better lentils, a partnership between University of Saskatchewan crop scientists and world-leading genomic big data company NRGene of Israel has successfully sequenced two wild lentil genomes-the largest legume genomes ever assembled.

The reverse stock split will be effective as of the close of business on November 7, 2017.

For the quarter ended September 30, 2017, the Company recorded revenues of $1,465,412, with $1,452,773 from the sale of products and $12,639 from installation and training services.

Total revenue for the three months ended September 30, 2017 was $10.3 million compared to $11.8 million generated during the comparable period in 2016.

OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families.

Groundbreaking ceremony spotlights local partnerships and the company’s dedication to serving expanding global business. [08-November-2017] LIBERTYVILLE, Ill., Nov. 8, 2017 /PRNewswire/ -- Hollister Incorporated, a global medical device manufacturer, today held a groundbreaking ceremony signifying the start of construction on a manufacturing plant in the K